A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...

Please provide your email address to receive an email when new articles are posted on . Finerenone reduced risk for CV death and worsening heart failure vs. placebo in this patient population. Pooled ...

Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has accepted ...

A key opinion leader provides insight into key HFpEF treatment strategies. This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, ...

BARCELONA, Spain—(UPDATED) Full results of the DELIVER trial, flanked by several other analyses, demonstrate that the sodium-glucose cotransporter 2 (SGLT2) inhibitors provide benefits to patients ...

An analysis of more than 12,000 patients has found that the SGLT2 inhibitors dapagliflozin and empagliflozin reduce cardiovascular death or hospitalization for heart failure by 20% in heart failure ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: A friend of mine has been diagnosed with “stiff heart” and ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...